UNSPSC 51381803: Talmetacin

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C27H20ClNO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6FY017I6S7, chemically known as 1,3-dihydro-3-oxo-1-isobenzofuranyl 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indole-3-acetate but generally known as talmetacin, which bears US NIH Compound Identifier 68564. European Medicines Agency schedules Talmetacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10808MIG.

UNSPSC 51381803 Talmetacin, a Commodity code, tracks state and local procurement of pharmaceutical products, though recent opportunities show minimal activity directly aligned with the talmetacin designation itself. The three most recent solicitations under this code reflect broader pharmaceutical supply activity: Seminole County, Florida procures naloxone and drug deactivation systems through competitive IFB; Texas Health and Human Services Commission seeks market intelligence on direct-to-manufacturer prescription programs via RFI; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicits generic multi-source pharmaceuticals and over-the-counter products through RFP. State and local issuing bodies pursuing pharmaceutical supply contracts span county health departments, state health agencies, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions. Seminole County represents the most straightforward model—direct procurement of specific pharmaceutical commodities for community health delivery—while MMCAP's structure shows how larger jurisdictions distribute pharmaceutical supply to multiple end-users through authorized wholesalers and contract manufacturers.

Geographic activity concentrates in Florida, Texas, and Minnesota based on recent postings, though MMCAP's cooperative structure extends coverage to Oregon and other participating states. Seminole County's IFB (IFB60459723LAS) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023 (note: this date appears inconsistent with the posting date of June 30, 2026 in the source). The Minnesota MMCAP RFP (S1070000015802) establishes multi-award contracts for generic pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to maintain relationships with three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification. Texas HHS's RFI (HHS0017013) differs structurally—posted April 3, 2026 with the same response deadline—and functions as exploratory market research rather than a binding procurement, gathering vendor capabilities for potential direct-to-manufacturer prescription fulfillment before issuing a formal RFP.